All News

Reimbursement

bluebird bio’s Zynteglo Approved by the FDA for Beta-Thalassemia
24 August 2022
bluebird bio’s Zynteglo Approved by the FDA for Beta-Thalassemia
bluebird bio has announced that
Market Access and Reimbursement Q&A with AviadoBio CEO Lisa Deschamps
21 June 2022
Market Access and Reimbursement Q&A with AviadoBio CEO Lisa Deschamps
Lisa Deschamps, AviadoBio CEO and
Market Access and Reimbursement Q&A with Nicola Redfern
21 June 2022
Market Access and Reimbursement Q&A with Nicola Redfern
Phacilitate's Advanced Therapies Europe speaker
Market Access and Reimbursement Q&A with Vice President of Novartis, Tay Salimullah
21 June 2022
Market Access and Reimbursement Q&A with Vice President of Novartis, Tay Salimullah
POPULAR NEWS ITEMS
Image
22 September 2022

CAR-T Manufacturing Challenges and How to Overcome Them

Image
22 September 2022

Lentiviral Vector Manufacture and Testing: Challenges and Solutions

Image
22 September 2022

Looking to the Future of CAR-T Cell Therapy Manufacture

Market Access Report 2022
1 June 2022
Market Access Report 2022
The Phacilitate team explores market
Gene Therapy May Be More Cost Effective for Treating Haemophilia B Than Other Methods
7 June 2021
Gene Therapy May Be More Cost Effective for Treating Haemophilia B Than Other Methods
A team from St Jude
Phacilitate’s Advanced Therapies Week Postponed Until June 2021
28 September 2020
Phacilitate’s Advanced Therapies Week Postponed Until June 2021
Despite Phacilitate’s enthusiasm and wholehearted
Phacilitate’s Rebrand Reinforces Commitment to The Advanced Therapies Community
9 September 2020
Phacilitate’s Rebrand Reinforces Commitment to The Advanced Therapies Community
London, July 9th 2020 -
Load more News
RECOMENDED TOPICS
Clinical Trials
Collaborations, Mergers & Acquisitions
Finance & Investment
Patient Access & Engagement
Regulatory & Standards
Reimbursement
Strategy
POPULAR NEWS ITEMS
Image

CAR-T Manufacturing Challenges and How to Overcome Them

Image

Lentiviral Vector Manufacture and Testing: Challenges and Solutions

Image

Looking to the Future of CAR-T Cell Therapy Manufacture